Shots:
- Saluda Medical has reported full commercial launch of EVA in the US following its approval in Dec 2024
- Saluda Medical will present new clinical data on EVA and the Evoke SmartLoop System at ASPN 2025, featuring 11 abstracts, one oral presentation, & over 37 total publications, incl. 36-month efficacy results from the EVOKE Study
- EVA objectively scans & analyzes the spinal cord to deliver personalized therapy with precision & it is compatible with all Evoke SmartLoop Systems, which optimize outcomes by sensing, measuring & adjusting stimulation based on each patient’s ECAP biomarker to maintain therapy
Ref: PRNewswire | Image: Saluda Medical| Press Release
Related News:- Johnson & Johnson MedTech Reports the US Launch of VOLT Wrist and Proximal Humerus Plating Systems
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
